vs
Cooper Companies (The)（COO）とチャールズ・リバー・ラボラトリーズ（CRL）の財務データ比較。上の社名をクリックして会社を切り替えられます
Cooper Companies (The)の直近四半期売上が大きい（$1.1B vs $994.2M、チャールズ・リバー・ラボラトリーズの約1.1倍）。Cooper Companies (The)の純利益率が高く（7.9% vs -27.8%、差は35.8%）。Cooper Companies (The)の前年同期比売上増加率が高い（4.6% vs -0.8%）。Cooper Companies (The)の直近四半期フリーキャッシュフローが多い（$149.9M vs $58.6M）。過去8四半期でCooper Companies (The)の売上複合成長率が高い（6.9% vs -0.9%）
クーパーカンパニーズ（CooperCompanies）は米国カリフォルニア州サンラモンに本社を置く世界的な医療機器企業です。コンタクトレンズを製造するクーパービジョンと、女性医療向けの医療機器、生殖・ゲノム製品を扱うクーパーサージカルの2つの事業部を展開しています。
チャールズ・リバー・ラボラトリーズ・インターナショナルは米国マサチューセッツ州ウィルミントンに本社を置く医薬・バイオテクノロジー分野の契約研究機関（CRO）です。1947年創業で、新薬、ワクチン、医療機器の開発向けに前臨床・臨床段階の検査サービスを提供しています。
COO vs CRL — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.1B | $994.2M |
| 純利益 | $84.6M | $-276.6M |
| 粗利率 | 61.1% | — |
| 営業利益率 | 13.2% | -28.5% |
| 純利益率 | 7.9% | -27.8% |
| 売上前年比 | 4.6% | -0.8% |
| 純利益前年比 | -28.0% | -28.9% |
| EPS（希薄化後） | $0.42 | $-5.57 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.1B | $994.2M | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.0B | $1.0B | ||
| Q1 25 | $964.7M | $984.2M | ||
| Q4 24 | $1.0B | $1.0B | ||
| Q3 24 | $1.0B | $1.0B | ||
| Q2 24 | $942.6M | $1.0B | ||
| Q1 24 | $931.6M | $1.0B |
| Q4 25 | $84.6M | $-276.6M | ||
| Q3 25 | $98.3M | $54.4M | ||
| Q2 25 | $87.7M | $52.3M | ||
| Q1 25 | $104.3M | $25.5M | ||
| Q4 24 | $117.5M | $-214.5M | ||
| Q3 24 | $104.7M | $69.7M | ||
| Q2 24 | $88.9M | $94.1M | ||
| Q1 24 | $81.2M | $73.0M |
| Q4 25 | 61.1% | — | ||
| Q3 25 | 65.3% | — | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 68.4% | — | ||
| Q4 24 | 66.5% | — | ||
| Q3 24 | 66.1% | 34.6% | ||
| Q2 24 | 67.0% | 34.5% | ||
| Q1 24 | 67.0% | 34.1% |
| Q4 25 | 13.2% | -28.5% | ||
| Q3 25 | 16.6% | 13.3% | ||
| Q2 25 | 18.4% | 9.7% | ||
| Q1 25 | 18.9% | 7.6% | ||
| Q4 24 | 19.5% | -16.7% | ||
| Q3 24 | 19.2% | 11.6% | ||
| Q2 24 | 17.2% | 14.8% | ||
| Q1 24 | 16.4% | 12.5% |
| Q4 25 | 7.9% | -27.8% | ||
| Q3 25 | 9.3% | 5.4% | ||
| Q2 25 | 8.7% | 5.1% | ||
| Q1 25 | 10.8% | 2.6% | ||
| Q4 24 | 11.5% | -21.4% | ||
| Q3 24 | 10.4% | 6.9% | ||
| Q2 24 | 9.4% | 9.2% | ||
| Q1 24 | 8.7% | 7.2% |
| Q4 25 | $0.42 | $-5.57 | ||
| Q3 25 | $0.49 | $1.10 | ||
| Q2 25 | $0.44 | $1.06 | ||
| Q1 25 | $0.52 | $0.50 | ||
| Q4 24 | $0.59 | $-4.17 | ||
| Q3 24 | $0.52 | $1.33 | ||
| Q2 24 | $0.44 | $1.74 | ||
| Q1 24 | $0.41 | $1.30 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $110.6M | $213.8M |
| 総負債低いほど良い | $2.5B | $2.1B |
| 株主資本純資産 | $8.2B | $3.2B |
| 総資産 | $12.4B | $7.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.30× | 0.68× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $110.6M | $213.8M | ||
| Q3 25 | $124.9M | $207.1M | ||
| Q2 25 | $116.2M | $182.8M | ||
| Q1 25 | $100.9M | $229.4M | ||
| Q4 24 | $107.6M | $194.6M | ||
| Q3 24 | $109.7M | $210.2M | ||
| Q2 24 | $112.4M | $179.2M | ||
| Q1 24 | $135.2M | $327.0M |
| Q4 25 | $2.5B | $2.1B | ||
| Q3 25 | $2.4B | $2.2B | ||
| Q2 25 | $2.5B | $2.3B | ||
| Q1 25 | $2.5B | $2.5B | ||
| Q4 24 | $2.6B | $2.2B | ||
| Q3 24 | $2.6B | $2.3B | ||
| Q2 24 | $2.7B | $2.4B | ||
| Q1 24 | $2.7B | $2.7B |
| Q4 25 | $8.2B | $3.2B | ||
| Q3 25 | $8.4B | $3.4B | ||
| Q2 25 | $8.3B | $3.4B | ||
| Q1 25 | $8.1B | $3.2B | ||
| Q4 24 | $8.1B | $3.5B | ||
| Q3 24 | $7.9B | $3.8B | ||
| Q2 24 | $7.8B | $3.7B | ||
| Q1 24 | $7.7B | $3.6B |
| Q4 25 | $12.4B | $7.1B | ||
| Q3 25 | $12.4B | $7.5B | ||
| Q2 25 | $12.4B | $7.6B | ||
| Q1 25 | $12.2B | $7.6B | ||
| Q4 24 | $12.3B | $7.5B | ||
| Q3 24 | $12.1B | $8.0B | ||
| Q2 24 | $12.0B | $7.9B | ||
| Q1 24 | $12.0B | $8.2B |
| Q4 25 | 0.30× | 0.68× | ||
| Q3 25 | 0.29× | 0.64× | ||
| Q2 25 | 0.30× | 0.70× | ||
| Q1 25 | 0.31× | 0.79× | ||
| Q4 24 | 0.32× | 0.65× | ||
| Q3 24 | 0.33× | 0.62× | ||
| Q2 24 | 0.34× | 0.65× | ||
| Q1 24 | 0.35× | 0.73× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $247.9M | $147.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $149.9M | $58.6M |
| FCFマージンFCF / 売上 | 14.1% | 5.9% |
| 設備投資強度設備投資 / 売上 | 9.2% | 8.9% |
| キャッシュ転換率営業CF / 純利益 | 2.93× | — |
| 直近12ヶ月FCF直近4四半期 | $433.7M | $518.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $247.9M | $147.5M | ||
| Q3 25 | $261.4M | $213.8M | ||
| Q2 25 | $96.2M | $204.6M | ||
| Q1 25 | $190.6M | $171.7M | ||
| Q4 24 | $268.1M | $159.4M | ||
| Q3 24 | $207.5M | $251.8M | ||
| Q2 24 | $111.0M | $193.5M | ||
| Q1 24 | $122.7M | $129.9M |
| Q4 25 | $149.9M | $58.6M | ||
| Q3 25 | $164.5M | $178.2M | ||
| Q2 25 | $18.1M | $169.3M | ||
| Q1 25 | $101.2M | $112.4M | ||
| Q4 24 | $128.1M | $83.7M | ||
| Q3 24 | $118.5M | $213.1M | ||
| Q2 24 | $36.9M | $154.0M | ||
| Q1 24 | $4.6M | $50.7M |
| Q4 25 | 14.1% | 5.9% | ||
| Q3 25 | 15.5% | 17.7% | ||
| Q2 25 | 1.8% | 16.4% | ||
| Q1 25 | 10.5% | 11.4% | ||
| Q4 24 | 12.6% | 8.4% | ||
| Q3 24 | 11.8% | 21.1% | ||
| Q2 24 | 3.9% | 15.0% | ||
| Q1 24 | 0.5% | 5.0% |
| Q4 25 | 9.2% | 8.9% | ||
| Q3 25 | 9.1% | 3.5% | ||
| Q2 25 | 7.8% | 3.4% | ||
| Q1 25 | 9.3% | 6.0% | ||
| Q4 24 | 13.7% | 7.5% | ||
| Q3 24 | 8.9% | 3.8% | ||
| Q2 24 | 7.9% | 3.8% | ||
| Q1 24 | 12.7% | 7.8% |
| Q4 25 | 2.93× | — | ||
| Q3 25 | 2.66× | 3.93× | ||
| Q2 25 | 1.10× | 3.91× | ||
| Q1 25 | 1.83× | 6.74× | ||
| Q4 24 | 2.28× | — | ||
| Q3 24 | 1.98× | 3.61× | ||
| Q2 24 | 1.25× | 2.06× | ||
| Q1 24 | 1.51× | 1.78× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
COO
| Sphere Other | $365.0M | 34% |
| Toric And Multifocal | $344.7M | 32% |
| Office And Surgical | $214.5M | 20% |
| Fertility | $140.9M | 13% |
CRL
| Discovery And Safety Assessment Segment | $591.6M | 60% |
| Manufacturing Support Segment | $196.4M | 20% |
| Transferred At Point In Time | $108.0M | 11% |
| Transferred Over Time | $98.3M | 10% |
